RealWorld Dynamix™: Biologic/Otezla Switching in Psoriasis US 2018 Spotlight
Biologic agents with alternate mechanisms of action (MOA) for the treatment of psoriasis are becoming increasingly popular, according to the second annual edition of Spherix Global Insights’ biologic/Otezla switching patient chart audit (n=1,006). With dermatologists now having increased (and more efficacious) options for psoriasis treatment, it’s not surprising the reported annual rate of patients switched from one biologic brand or Otezla to another brand is up significantly over the prior year.
Efficacy is the most common trigger for a switch, though the switch patterns differ dramatically depending on whether it was a primary vs. secondary efficacy issue, with other factors, such as patient and payer influence, also playing a role. Reasons for new brand choice also vary between classes of treatment. View complimentary data highlights full 2018 report below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.